SKStacy Ann Stratemann Killen

Stacy Ann Stratemann Killen

*This is an algorithmically generated author record based on publicly available information.

Stacy Ann Stratemann Killen has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Outcomes of Hypoplastic Left Heart Syndrome by Subtype and Presence of Ventriculocoronary Connections: A Fetal Heart Society Multicenter Retrospective Study

    by David M. Barris, Lindsay R. Freud, Patrick E. Day, Shaine A. Morris, Keila N. Lopez, Ann Kavanaugh-McHugh, Stacy A.S. Killen, Shabnam Peyvandi, Flora Nuñez Gallegos, Anita J. Moon-Grady, et al.

    BACKGROUND: Hypoplastic left heart syndrome (HLHS) is classified by anatomic subtype: mitral atresia and aortic atresia (MA/AA), mitral stenosis and aortic atresia (MS/AA), and mitral stenosis and aortic stenosis (MS/AS). The MS/AA subtype is associated with ventriculocoronary connections (VCCs). We assessed whether specific HLHS subtypes are associated with an increased risk of mortality and whether this risk is stratified by VCCs identified during fetal or postnatal echocardiography. We also assessed whether the type of neonatal intervention performed modified the risk. METHODS: We performed a multicenter retrospective cohort study of fetuses and infants P =0.784). CONCLUSIONS: In a large, multicenter cohort of HLHS patients, the MS/AA subtype with VCCs had the lowest TFS. Prenatal diagnosis of VCCs was associated with a lower TFS. This study underscores the prognostic value of assessing for VCCs in patients with HLHS both before and after birth.

  • Open Access

    Ambulatory Fetal Heart Rate and Rhythm Monitoring for Pregnancies at Risk for Fetal Arrhythmias: Perspectives from the Fetal Heart Society

    by Stacy A. S. Killen, Sheetal Patel, Nitin Madan, Maria Kiaffas, Shardha Srinivasan, Jacqueline Shuplock, Joyce Johnson, Whitnee Hogan, Miwa Geiger, Lisa Hornberger, et al.

    Fetal arrhythmias, including tachycardias, bradycardias and irregular rhythms, may require close surveillance and management to prevent fetal heart failure, premature delivery and stillbirth. With early detection and appropriate management of pathological fetal rhythms, 90–95% of fetuses with even high-risk arrhythmias are live-born and can be delivered at term gestation. Fetal heart rate monitoring (FHRM) is a feasible method for ambulatory detection of new-onset or recurrent arrhythmias. When indications for FHRM are met, prescribed monitoring, guided and supported by the healthcare team, can empower pregnant individuals in the management of their pregnancies. Despite several studies showing utility of ambulatory FHRM, fetal cardiologists and perinatologists face challenges in successfully implementing FHRM programs. Under the auspices of the Fetal Heart Society, the Fetal Cardiology Program Leaders Committee formed a writing group to develop a consensus-based ambulatory FHRM process to be used as a guide for providers caring for pregnancies complicated by or at risk of manifesting fetal arrhythmias.

  • Open Access

    Management of fetal supraventricular tachycardia

    by Stacy Ann Stratemann Killen


  • Two Pediatric Cases of Left-sided, Native-valve Streptococcus pneumoniae Endocarditis

    by Natalya Beneschott, Rachel K. Duncan, Sophie E. Katz, Ritu Banerjee, Rachel T. Sullivan, Stacy A. S. Md Killen, Leigh M. Howard

  • Open Access

    Diagnosis and Management of Fetal Arrhythmias in the Current Era

    by Stacy A. S. Killen, Janette F. Strasburger

    Diagnosis and management of fetal arrhythmias have changed over the past 40–50 years since propranolol was first used to treat fetal tachycardia in 1975 and when first attempts were made at in utero pacing for complete heart block in 1986. Ongoing clinical trials, including the FAST therapy trial for fetal tachycardia and the STOP-BLOQ trial for anti-Ro-mediated fetal heart block, are working to improve diagnosis and management of fetal arrhythmias for both mother and fetus. We are also learning more about how “silent arrhythmias”, like long QT syndrome and other inherited channelopathies, may be identified by recognizing “subtle” abnormalities in fetal heart rate, and while echocardiography yet remains the primary tool for diagnosing fetal arrhythmias, research efforts continue to advance the clinical envelope for fetal electrocardiography and fetal magnetocardiography. Pharmacologic management of fetal arrhythmias remains one of the most successful achievements of fetal intervention. Patience, vigilance, and multidisciplinary collaboration are key to successful diagnosis and treatment.


  • Open Access

    Management of Ebstein Anomaly in the Current Era: The Story of One Fetus and the Collaboration of Many—A Case Report

    by Ann Kavanaugh-McHugh, Lisa C. Zuckerwise, Stacy A. S. Killen, Emily A. Morris, Rachel T. Sullivan, Mhd Wael Alrifai, David P. Bichell, Melissa Smith-Parrish, Lindsay Freud

    Collaborative multicenter research has significantly increased our understanding of fetal Ebstein anomaly, delineating risk factors for adverse outcomes as well as predictors of postnatal management. These data are incorporated into prenatal care and therapeutic strategies and inform family counseling and delivery planning to optimize care. This report details the translation of findings from multicenter studies into multidisciplinary prenatal care for a fetus with Ebstein anomaly, supraventricular tachycardia, and a circular shunt, including transplacental therapy to control arrhythmias and achieve ductal constriction, informed and coordinated delivery room management, and planned univentricular surgical palliation.


  • Postoperative Morbidity and Interstage Hemodynamics Following Stage I Palliation in Patients with Turner Syndrome and Hypoplastic Left Heart Syndrome

    by Sandra Kikano, Sarah Fuchs, Andres Contreras Vega, Ann Kavanaugh-McHugh, David Bichell, Stacy A. S. Killen

    Background Turner syndrome (TS) is associated with left-sided cardiac lesions, including hypoplastic left heart syndrome (HLHS). Mortality as high as 80–90% has been reported following stage I single-ventricle palliation (S1P) in patients with TS and HLHS (TS + HLHS). The specific factors that relate to poor outcomes are not well understood. Methods This is a single-center, retrospective cohort study that includes 197 patients with HLHS who underwent S1P between 2008 and 2022. The clinical outcomes and interstage hemodynamics of TS + HLHS patients (N = 11) were compared with HLHS without TS (TS-HLHS), (N = 186). Results Of the 11 TS + HLHS patients, 10 underwent S1P; 4 underwent Glenn and 1 had hemodynamics considered prohibitive for Glenn; only 1 survived to Fontan palliation. Post-S1P mortality was higher in TS + HLHS (60 v 25%, p = 0.017). Following S1P, TS + HLHS had higher rates of postoperative ECMO (70 v 28%, p = 0.006), surgical necrotizing enterocolitis (20 v 3%, p = 0.007), peritoneal drain placement (70 v 31%, p = 0.012), urinary tract infection (30 v 9%, p = 0.035), and ICU readmissions (median 5 v 1, p = 0.035). Interstage hemodynamics demonstrated higher right ventricular end diastolic, (11 v 8mmHg, p = 0.033), mean pulmonary artery (20 v 13mmHg) (p = 0.002), and left atrial pressures (9 v 6mmHg, p = 0.047) in TS + HLHS. Conclusion High mortality rates are described in TS + HLHS patients following S1P. In our cohort, despite most surviving more than 30 days post-S1P, long-term survival remained poor. Interstage catheterization data suggest poor physiologic candidacy for subsequent stages of single-ventricle palliation. Understanding the clinical and hemodynamic factors related to poor outcomes in TS + HLHS will help inform management for this population.


  • Open Access

    Effects of cohort, genotype, variant, and maternal β-blocker treatment on foetal heart rate predictors of inherited long QT syndrome

    by Alexander M Kaizer, Annika Winbo, Sally-Ann B Clur, Susan P Etheridge, Michael J Ackerman, Hitoshi Horigome, Ulrike Herberg, Federica Dagradi, Carla Spazzolini, Stacy A S Killen, et al.

    In long QT syndrome (LQTS), primary prevention improves outcome; thus, early identification is key. The most common LQTS phenotype is a foetal heart rate (FHR) < 3rd percentile for gestational age (GA) but the effects of cohort, genotype, variant, and maternal β-blocker therapy on FHR are unknown. We assessed the influence of these factors on FHR in pregnancies with familial LQTS and developed a FHR/GA threshold for LQTS. In an international cohort of pregnancies in which one parent had LQTS, LQTS genotype, familial variant, and maternal β-blocker effects on FHR were assessed. We developed a testing algorithm for LQTS using FHR and GA as continuous predictors. Data included 1966 FHRs at 7–42 weeks’ GA from 267 pregnancies/164 LQTS families [220 LQTS type 1 (LQT1), 35 LQTS type 2 (LQT2), and 12 LQTS type 3 (LQT3)]. The FHRs were significantly lower in LQT1 and LQT2 but not LQT3 or LQTS negative. The LQT1 variants with non-nonsense and severe function loss (current density or β-adrenergic response) had lower FHR. Maternal β-blockers potentiated bradycardia in LQT1 and LQT2 but did not affect FHR in LQTS negative. A FHR/GA threshold predicted LQT1 and LQT2 with 74.9% accuracy, 71% sensitivity, and 81% specificity. Genotype, LQT1 variant, and maternal β-blocker therapy affect FHR. A predictive threshold of FHR/GA significantly improves the accuracy, sensitivity, and specificity for LQT1 and LQT2, above the infant’s a priori 50% probability. We speculate this model may be useful in screening for LQTS in perinatal subjects without a known LQTS family history. Summary of findings from the manuscript.


  • Prenatally diagnosed coronary artery abnormalities in hypoplastic left heart syndrome are associated with a higher probability of heart transplantation

    by Elena Rueda‐De‐Leon, Stacy A. S. Killen, Jonathan H. Soslow, M. Kelly McHugh, Sarah R. Fuchs, Ann Kavanaugh‐McHugh

    Objective Coronary artery abnormalities (CA) occur in patients with hypoplastic left heart syndrome (HLHS) and may be associated with higher mortality and heart transplantation (HT). We aimed to determine whether fetuses with HLHS and prenatal CA have a higher risk of death or HT. Methods We performed a retrospective review of fetal echocardiograms with HLHS from 2011 to 2018. We excluded fetuses with ventricular septal defects, elective termination, death in utero, planned postnatal non-intervention, or absent follow-up data. Presence or absence of CA was determined by review of serial fetal echocardiograms. Survival analysis was used to evaluate the relationship between prenatal CA and death or HT. Results Of 86 patients with fetal HLHS, 11 had prenatal diagnosis of CA. Of these, six required HT and five died (one after undergoing HT); only one remains alive without HT. Of those without prenatal CA (n = 75), 25 died and 7 underwent HT. Patients with prenatal diagnosis of HLHS and CA had a significantly increased likelihood of death or HT (p-value <0.05). Conclusion Prenatal diagnosis of CA in our cohort of patients with HLHS was associated with increased risk of death or HT. These data have significance for prenatal counseling and postnatal management.


  • Transient fetal atrioventricular block: A series of four cases and approach to management

    by Sandra D. Kikano, Stacy A. S. Killen

    Introduction: Fetal atrioventricular block (AVB) is a failure of conduction from atria to ventricles. Immune‐ and nonimmune‐mediated forms occur, especially in association with congenital heart disease. Second‐degree (2°) AVB may be reversible with dexamethasone and intravenous immunoglobulin in immune‐mediated disease. However, once third‐degree AVB develops, it is deemed irreversible with need for a pacemaker and risk for cardiomyopathy. Rarely, 2° AVB is a transient, benign phenomenon in the immature conduction system. Few case series of transient AVB have been reported, but a management approach has not been defined.Methods/Results/Conclusion: We report four patients with self‐resolving, nonimmune fetal AVB and outline a management strategy.